Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia.

Tsamadou C, Fürst D, Wang T, He N, Lee SJ, Spellman SR, Fleischhauer K, Hsu KC, Paczesny S, Verneris MR, Schrezenmeier H, Mytilineos J.

Biol Blood Marrow Transplant. 2019 Aug 16. pii: S1083-8791(19)30521-X. doi: 10.1016/j.bbmt.2019.08.007. [Epub ahead of print]

2.

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.

Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, Bhojwani D, Burke MJ, Verneris MR.

Blood Adv. 2019 Jul 9;3(13):1926-1929. doi: 10.1182/bloodadvances.2018025726. No abstract available.

3.

The Human TET2 Gene Contains Three Distinct Promoter Regions With Differing Tissue and Developmental Specificities.

Lou H, Li H, Ho KJ, Cai LL, Huang AS, Shank TR, Verneris MR, Nickerson ML, Dean M, Anderson SK.

Front Cell Dev Biol. 2019 Jun 7;7:99. doi: 10.3389/fcell.2019.00099. eCollection 2019.

4.

Correction: A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation.

Fernandez IZ, Baxter RM, Garcia-Perez JE, Vendrame E, Ranganath T, Kong DS, Lundquist K, Nguyen T, Ogolla S, Black J, Galambos C, Gumbart JC, Dawany N, Kelsen JR, de Zoeten EF, Quinones R, Eissa H, Verneris MR, Sullivan KE, Rochford R, Blish CA, Kedl RM, Dutmer CM, Hsieh EWY.

J Exp Med. 2019 Jun 3;216(6):1465. doi: 10.1084/jem.2018201505102019c. Epub 2019 May 14. No abstract available.

5.

A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation.

Fernandez IZ, Baxter RM, Garcia-Perez JE, Vendrame E, Ranganath T, Kong DS, Lundquist K, Nguyen T, Ogolla S, Black J, Galambos C, Gumbart JC, Dawany N, Kelsen JR, de Zoeten EF, Quinones R, Eissa H, Verneris MR, Sullivan KE, Rochford R, Blish CA, Kedl RM, Dutmer CM, Hsieh EWY.

J Exp Med. 2019 Jun 3;216(6):1255-1267. doi: 10.1084/jem.20182015. Epub 2019 Apr 30. Erratum in: J Exp Med. 2019 May 14;:.

PMID:
31040184
6.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia.

Keating AK, Langenhorst J, Wagner JE, Page KM, Veys P, Wynn RF, Stefanski H, Elfeky R, Giller R, Mitchell R, Milano F, O'Brien TA, Dahlberg A, Delaney C, Kurtzberg J, Verneris MR, Boelens JJ.

Blood Adv. 2019 Apr 9;3(7):1118-1128. doi: 10.1182/bloodadvances.2018025908.

7.

Transient Expression of GATA3 in Hematopoietic Stem Cells Facilitates Helper Innate Lymphoid Cell Differentiation.

Tufa DM, Yingst AM, Shank T, Shim S, Trahan GD, Lake J, Woods R, Jones KL, Verneris MR.

Front Immunol. 2019 Mar 21;10:510. doi: 10.3389/fimmu.2019.00510. eCollection 2019.

8.

Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection.

Green JS, Shanley RM, Brunstein CG, Young JH, Verneris MR.

Transpl Infect Dis. 2019 Jun;21(3):e13070. doi: 10.1111/tid.13070. Epub 2019 Mar 29.

PMID:
30864271
9.

Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors.

Koo J, Silverman S, Nuechterlein B, Keating AK, Verneris MR, Foreman NK, Mulcahy Levy JM.

Bone Marrow Transplant. 2019 Feb 19. doi: 10.1038/s41409-019-0479-3. [Epub ahead of print]

PMID:
30783209
10.

Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients.

Sopfe J, Pyle L, Keating AK, Campbell K, Liu AK, Wadwa RP, Verneris MR, Giller RH, Forlenza GP.

Blood Adv. 2019 Feb 12;3(3):350-359. doi: 10.1182/bloodadvances.2018021014.

11.

Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes.

Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, Yingst A, Weisdorf DJ, Blazar BR, Miller JS, Wagner JE, Verneris MR.

Biol Blood Marrow Transplant. 2019 May;25(5):883-890. doi: 10.1016/j.bbmt.2019.01.003. Epub 2019 Jan 6.

PMID:
30625388
12.

Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study.

Askar M, Sayer D, Wang T, Haagenson M, Spellman SR, Lee SJ, Madbouly A, Fleischhauer K, Hsu KC, Verneris MR, Thomas D, Zhang A, Sobecks RM, Majhail NS; Center for International Blood and Marrow Transplant Research Immunology Working Committee.

Biol Blood Marrow Transplant. 2019 Apr;25(4):664-672. doi: 10.1016/j.bbmt.2018.12.008. Epub 2018 Dec 8.

PMID:
30537553
13.

The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR.

Pingel J, Wang T, Hagenlocher Y, Hernández-Frederick CJ, Nagler A, Haagenson MD, Fleischhauer K, Hsu KC, Verneris MR, Lee SJ, Mohty M, Polge E, Spellman SR, Schmidt AH, van Rood JJ.

Bone Marrow Transplant. 2019 Jun;54(6):849-857. doi: 10.1038/s41409-018-0345-8. Epub 2018 Oct 2.

PMID:
30279575
14.

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, Winckler W.

Nat Med. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1.

PMID:
30275569
15.

Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia.

Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, Diaz MA, Badawy SM, Broglie L, Brown V, Dvorak CC, Gonzalez-Vicent M, Hashem H, Hayashi RJ, Jacobsohn DA, Kent MW, Li CK, Margossian SP, Martin PL, Mehta P, Myers K, Olsson R, Page K, Pulsipher MA, Shaw PJ, Smith AR, Triplett BM, Verneris MR, Eapen M.

Biol Blood Marrow Transplant. 2019 Feb;25(2):301-306. doi: 10.1016/j.bbmt.2018.09.016. Epub 2018 Sep 19.

PMID:
30244103
16.

Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.

Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, Verneris MR.

Biol Blood Marrow Transplant. 2019 Jan;25(1):12-18. doi: 10.1016/j.bbmt.2018.08.011. Epub 2018 Aug 23.

PMID:
30144561
17.

In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance.

Arrieta-Bolaños E, Crivello P, Shaw BE, Ahn KW, Wang HL, Verneris MR, Hsu KC, Pidala J, Lee SJ, Fleischhauer K, Spellman SR.

Blood Adv. 2018 Jul 24;2(14):1773-1783. doi: 10.1182/bloodadvances.2018019620.

18.

Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection.

Rothenberger M, Wagner JE, Haase A, Richman D, Grzywacz B, Strain M, Lada S, Estes J, Fletcher CV, Podany AT, Anderson J, Schmidt T, Wietgrefe S, Schacker T, Verneris MR.

Open Forum Infect Dis. 2018 May 22;5(5):ofy090. doi: 10.1093/ofid/ofy090. eCollection 2018 May.

19.

Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.

Nemecek ER, Hilger RA, Adams A, Shaw BE, Kiefer D, Le-Rademacher J, Levine JE, Yanik G, Leung W, Talano JA, Haut P, Delgado D, Kapoor N, Petrovic A, Adams R, Hanna R, Rangarajan H, Dalal J, Chewning J, Verneris MR, Epstein S, Burroughs L, Perez-Albuerne ED, Pulsipher MA, Delaney C.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1651-1656. doi: 10.1016/j.bbmt.2018.04.025. Epub 2018 May 9.

20.

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.

Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, Mehta RS, Warlick E, Cooley SA, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR.

Blood Adv. 2018 Apr 24;2(8):909-922. doi: 10.1182/bloodadvances.2017014464.

21.

Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors.

Pilbeam K, Wang H, Taras E, Bergerson RJ, Ettestad B, DeFor T, Borgatti A, Vallera DA, Verneris MR.

Oncotarget. 2017 Sep 23;9(15):11938-11947. doi: 10.18632/oncotarget.21187. eCollection 2018 Feb 23.

22.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS.

Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20.

23.

Evaluation of a Machine Learning-Based Prognostic Model for Unrelated Hematopoietic Cell Transplantation Donor Selection.

Buturovic L, Shelton J, Spellman SR, Wang T, Friedman L, Loftus D, Hesterberg L, Woodring T, Fleischhauer K, Hsu KC, Verneris MR, Haagenson M, Lee SJ.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1299-1306. doi: 10.1016/j.bbmt.2018.01.038. Epub 2018 Feb 2.

24.

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA.

N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.

25.

Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.

Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR.

Bone Marrow Transplant. 2018 Jul;53(7):932-937. doi: 10.1038/s41409-018-0100-1. Epub 2018 Jan 30. No abstract available.

26.

No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia.

Gadalla SM, Wang T, Loftus D, Friedman L, Dagnall C, Haagenson M, Spellman SR, Buturovic L, Blauwkamp M, Shelton J, Fleischhauer K, Hsu KC, Verneris MR, Krstajic D, Hicks B, Jones K, Lee SJ, Savage SA.

Bone Marrow Transplant. 2018 Apr;53(4):383-391. doi: 10.1038/s41409-017-0029-9. Epub 2017 Dec 21.

27.

Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells.

Williams RL, Cooley S, Bachanova V, Blazar BR, Weisdorf DJ, Miller JS, Verneris MR.

Biol Blood Marrow Transplant. 2018 Mar;24(3):618-622. doi: 10.1016/j.bbmt.2017.11.022. Epub 2017 Nov 29.

28.

Fewer Circulating Natural Killer Cells 28 Days After Double Cord Blood Transplantation Predicts Inferior Survival and IL-15 Response.

Bergerson RJ, Williams R, Wang H, Shanley R, Colbenson G, Kerber A, Cooley S, Curtsinger J, Felices M, Miller JS, Verneris MR.

Blood Adv. 2016 Dec 27;1(3):208-218. doi: 10.1182/bloodadvances.2016000158. Epub 2016 Oct 30.

29.

Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.

Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG.

Bone Marrow Transplant. 2018 Jan;53(1):64-68. doi: 10.1038/bmt.2017.236. Epub 2017 Oct 23.

30.

Whole-Body Distribution of Leukemia and Functional Total Marrow Irradiation Based on FLT-PET and Dual-Energy CT.

Magome T, Froelich J, Holtan SG, Takahashi Y, Verneris MR, Brown K, Dusenbery K, Wong J, Hui SK.

Mol Imaging. 2017 Jan-Dec;16:1536012117732203. doi: 10.1177/1536012117732203.

31.

Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies.

Touma W, Brunstein CG, Cao Q, Miller JS, Curtsinger J, Verneris MR, Bachanova V.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1925-1931. doi: 10.1016/j.bbmt.2017.07.008. Epub 2017 Jul 17.

32.

Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.

Holtan SG, Newell LF, Cutler C, Verneris MR, DeFor TE, Wu J, Howard A, MacMillan ML, Antin JH, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A.

Bone Marrow Transplant. 2017 Sep;52(9):1300-1303. doi: 10.1038/bmt.2017.89. Epub 2017 Jun 5.

33.

Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells.

Angelos MG, Ruh PN, Webber BR, Blum RH, Ryan CD, Bendzick L, Shim S, Yingst AM, Tufa DM, Verneris MR, Kaufman DS.

Blood. 2017 Jun 29;129(26):3428-3439. doi: 10.1182/blood-2016-07-730440. Epub 2017 May 22.

34.

Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Hui S, Brunstein C, Takahashi Y, DeFor T, Holtan SG, Bachanova V, Wilke C, Zuro D, Ustun C, Weisdorf D, Dusenbery K, Verneris MR.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1110-1116. doi: 10.1016/j.bbmt.2017.04.002. Epub 2017 Apr 7.

35.

Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.

Dourado KMC, Baik J, Oliveira VKP, Beltrame M, Yamamoto A, Theuer CP, Figueiredo CAV, Verneris MR, Perlingeiro RCR.

Blood. 2017 May 4;129(18):2526-2536. doi: 10.1182/blood-2017-01-763581. Epub 2017 Mar 28.

36.

Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes.

Madbouly A, Wang T, Haagenson M, Paunic V, Vierra-Green C, Fleischhauer K, Hsu KC, Verneris MR, Majhail NS, Lee SJ, Spellman SR, Maiers M.

Biol Blood Marrow Transplant. 2017 Jun;23(6):1029-1037. doi: 10.1016/j.bbmt.2017.02.019. Epub 2017 Mar 2.

37.

Impact of Delayed Infusion Time in Umbilical Cord Blood Transplantation.

Mitchell R, Wagner JE, Brunstein C, Cao Q, McKenna DH, Verneris MR.

Biol Blood Marrow Transplant. 2017 May;23(5):836-839. doi: 10.1016/j.bbmt.2017.02.010. Epub 2017 Feb 15.

38.

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL.

N Engl J Med. 2017 Feb 9;376(6):536-547. doi: 10.1056/NEJMoa1611604.

39.

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.

Brunstein CG, Cutler CS, DeFor TE, Kim H, Bejanyan N, Garfall A, Verneris MR, Chen YB, Warlick ED, Spitzer T, Miller JS, Antin JH, Weisdorf DJ, Soiffer R, Wagner JE, Ballen KK.

Biol Blood Marrow Transplant. 2017 Jan;23(1):126-133. doi: 10.1016/j.bbmt.2016.10.018. Epub 2016 Oct 29.

40.

Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation.

He F, Verneris MR, Cooley S, Blazar BR, MacMillan ML, Newell LF, Panoskaltsis-Mortari A, DeFor T, Weisdorf DJ, Holtan SG.

Bone Marrow Transplant. 2017 Feb;52(2):301-303. doi: 10.1038/bmt.2016.261. Epub 2016 Nov 21. No abstract available.

41.

A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.

Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K.

Blood. 2017 Feb 9;129(6):740-758. doi: 10.1182/blood-2016-05-713347. Epub 2016 Nov 7.

42.

Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes.

Hoff GA, Fischer JC, Hsu K, Cooley S, Miller JS, Wang T, Haagenson M, Spellman S, Lee SJ, Uhrberg M, Venstrom JM, Verneris MR.

Biol Blood Marrow Transplant. 2017 Jan;23(1):153-160. doi: 10.1016/j.bbmt.2016.09.028. Epub 2016 Oct 13.

43.

Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity.

Lu H, Bhoopatiraju S, Wang H, Schmitz NP, Wang X, Freeman MJ, Forster CL, Verneris MR, Linden MA, Hallstrom TC.

Oncotarget. 2016 Nov 15;7(46):76047-76061. doi: 10.18632/oncotarget.12583.

44.

CD4+ T Cells Coexpressing CD134 (OX40) Harbor Significantly Increased Levels of Human Herpesvirus 6B DNA Following Umbilical Cord Blood Transplantation.

Pritchett JC, Green JS, Thomm AM, Knox KK, Verneris MR, Lund TC.

J Infect Dis. 2016 Dec 15;214(12):1911-1915. Epub 2016 Oct 4.

45.

Evaluation of Functional Marrow Irradiation Based on Skeletal Marrow Composition Obtained Using Dual-Energy Computed Tomography.

Magome T, Froelich J, Takahashi Y, Arentsen L, Holtan S, Verneris MR, Brown K, Haga A, Nakagawa K, Holter Chakrabarty JL, Giebel S, Wong J, Dusenbery K, Storme G, Hui SK.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):679-87. doi: 10.1016/j.ijrobp.2016.06.2459. Epub 2016 Jul 6.

46.

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.

Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2025-2030. doi: 10.1016/j.bbmt.2016.08.005. Epub 2016 Aug 9.

47.

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.

Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, Verneris MR, Blazar BR, Miller JS.

Cancer Res. 2016 Oct 1;76(19):5696-5706. Epub 2016 Aug 8.

48.

Erratum to: "Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction" [Biol Blood Marrow Transplant 2016;22:1159-1166].

Turcotte LM, Yingst A, Verneris MR.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2286. doi: 10.1016/j.bbmt.2016.07.017. Epub 2016 Aug 5. No abstract available.

49.

YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome.

Kornblit B, Wang T, Lee SJ, Spellman SR, Zhu X, Fleischhauer K, Müller C, Verneris MR, Müller K, Johansen JS, Vindelov L, Garred P.

Bone Marrow Transplant. 2016 Dec;51(12):1556-1560. doi: 10.1038/bmt.2016.192. Epub 2016 Jul 18.

50.

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.

Ballen K, Woo Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M, Antin J, Bhatt AS, Boeckh M, Chen G, Dandoy C, George B, Laughlin MJ, Lazarus HM, MacMillan ML, Margolis DA, Marks DI, Norkin M, Rosenthal J, Saad A, Savani B, Schouten HC, Storek J, Szabolcs P, Ustun C, Verneris MR, Waller EK, Weisdorf DJ, Williams KM, Wingard JR, Wirk B, Wolfs T, Young JH, Auletta J, Komanduri KV, Lindemans C, Riches ML.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1636-1645. doi: 10.1016/j.bbmt.2016.06.012. Epub 2016 Jun 22.

Supplemental Content

Loading ...
Support Center